Back to News
Market Impact: 0.2
Alaunos Therapeutics, Inc. Believes It Regained Nasdaq Compliance Following $350.0 million Financing
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Alaunos Therapeutics said it believes it has regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement. Nasdaq had issued a deficiency letter on April 9, 2026, after the company reported equity below the threshold; the article text is truncated before giving the complete amount.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
TCRT0.20
More News
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- OpenAI nears up to $30 billion funding round at $1.25 trillion valuation led by UAE investors
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- SpaceX records $561 million investment gain from stake in Elon Musk's Boring Co.
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Can ChatGPT or Claude Replace a Research Platform?
- How the 2026 Milan-Cortina Winter Olympics Will Reshape Company Revenues and Stock Performance